ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II (ADVISEII)
This study has been completed.
Information provided by (Responsible Party):
First received: November 16, 2012
Last updated: August 5, 2014
Last verified: August 2014
To assess the clinical value of iFR to characterize, without concomitant administration of hyperemic agents and outside a specified range of iFR values, coronary stenosis severity as determined with fractional flow reserve (FFR)
||Observational Model: Case-Only
Time Perspective: Prospective
||A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Primary Outcome Measures:
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2013 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years to 85 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patient receiving a standard of care FFR measurment in the cath lab setting.
- - Patient must be > 18 and < 85 years of age
- Willing to participate and able to understand, read and sign the informed consent document before the planned procedure
- Eligible for coronary angiography and/or percutaneous coronary intervention
- Coronary artery disease with at least 1 or more visually assessed coronary stenoses (>40% diameter stenosis) in native major epicardial vessel or its branches by coronary angiogram.
- Stable angina or acute coronary syndromes (non-culprit vessels only and outside of primary intervention during acute myocardial infarction)
- - Known contraindication to adenosine administration
- Implanted temporary or permanent artificial pacemakers, Left Bundle Branch Block (LBBB), 1st and 2nd degree AV Block
- STEMI or non STEMI within 48 hours of procedure
- Any contraindications for FFR interrogation or percutaneous coronary intervention (PCI) as determined by the investigator
- Severe vessel tortuosity and/or severe calcification by angiogram
- Significant valvular pathology (moderate or severe AS/AR/MS/MR)
- Previous Coronary Artery Bypass surgery with patent grafts to the interrogated vessel
- Weight >200kg (441 lbs.)
- Hemodynamic instability at the time of intervention (heart rate<50 beats per minute, systolic blood pressure <90mmHg) balloon pump
- Significant hepatic disease, renal disease, lung disease (pulmonary chronic pulmonary obstructive disease) and/or malignant disease with unfavorable prognosis or presenting with abnormal serum laboratory values that the physician believes is clinically significant
- Contraindication to antithrombotic regimen or anticoagulation therapy
- History of or known reaction or sensitivity to contrast agent and is unable to be pre-medicated
- Left main stenosis, tandem stenosis separated by more than 5 mm that require separate pressure guide wire interrogation or PCI (not to be interrogated or treated as a single stenosis), or total occlusions
- Known Left ventricular ejection fraction (LVEF) <30%
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01740895
||Javier Escaned, MD
||Hospital Cl¡nico San Carlos Madrid Spain
||Amir Lerman, MD
||Mayo Clinic Rochester MN USA
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 16, 2012
||August 5, 2014
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 16, 2014